BioNTech (NASDAQ:BNTX) Raised to “Buy” at The Goldman Sachs Group

BioNTech (NASDAQ:BNTX) was upgraded by investment analysts at The Goldman Sachs Group from a “neutral” rating to a “buy” rating in a research note issued to investors on Friday, Marketbeat reports. The brokerage currently has a $137.00 target price on the stock, up from their previous target price of $90.00. The Goldman Sachs Group’s target price would indicate a potential upside of 23.83% from the company’s current price.

A number of other research firms have also recently weighed in on BNTX. Deutsche Bank Aktiengesellschaft lifted their target price on shares of BioNTech from $95.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, September 19th. Bank of America lifted their price target on shares of BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 16th. HC Wainwright lifted their price target on shares of BioNTech from $113.00 to $150.00 and gave the company a “buy” rating in a report on Monday, October 7th. JPMorgan Chase & Co. reduced their price target on shares of BioNTech from $125.00 to $124.00 and set a “neutral” rating on the stock in a report on Monday, November 4th. Finally, Hsbc Global Res upgraded shares of BioNTech from a “hold” rating to a “strong-buy” rating in a report on Friday, August 2nd. Four analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $137.54.

BioNTech Stock Up 2.6 %

BNTX opened at $110.64 on Friday. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.33. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The firm’s fifty day moving average is $111.85 and its 200 day moving average is $96.60. The stock has a market cap of $26.31 billion, a price-to-earnings ratio of -52.69 and a beta of 0.26.

BioNTech (NASDAQ:BNTX) last released its earnings results on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company had revenue of $1.24 billion for the quarter, compared to analysts’ expectations of $514.08 million. During the same quarter in the previous year, the company earned $0.73 EPS. BioNTech’s revenue for the quarter was up 38.9% on a year-over-year basis. On average, sell-side analysts forecast that BioNTech will post -3.32 earnings per share for the current fiscal year.

Institutional Trading of BioNTech

A number of large investors have recently made changes to their positions in BNTX. Covestor Ltd grew its holdings in BioNTech by 47.2% during the 1st quarter. Covestor Ltd now owns 415 shares of the company’s stock valued at $38,000 after purchasing an additional 133 shares during the last quarter. GAMMA Investing LLC grew its holdings in BioNTech by 86.9% during the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after purchasing an additional 238 shares during the last quarter. EverSource Wealth Advisors LLC grew its holdings in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the last quarter. Planning Capital Management Corp grew its holdings in BioNTech by 45,000.0% during the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock valued at $54,000 after purchasing an additional 450 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in BioNTech by 491.1% during the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock valued at $55,000 after purchasing an additional 388 shares during the last quarter. 15.52% of the stock is currently owned by institutional investors.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.